Filing Details
- Accession Number:
- 0001140361-20-002937
- Form Type:
- 13G Filing
- Publication Date:
- 2020-02-12 16:47:01
- Filed By:
- Maetzold Derek J
- Company:
- Castle Biosciences Inc (NASDAQ:CSTL)
- Filing Date:
- 2020-02-12
- SEC Url:
- 13G Filing
Ownership Summary
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Derek J. Maetzold | 1,953,215 | 0 | 1,953,215 | 0 | 1,953,215 | 11.3% |
Filing
| | UNITED STATES | |
| | SECURITIES AND EXCHANGE COMMISSION | |
| | Washington, D.C. 20549 | |
| | | |
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. __)
CASTLE BIOSCIENCES, INC.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
14843C 105
(CUSIP Number)
December 31, 2019
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
| ☐ | Rule 13d-1(b) |
| ☐ | Rule 13d-1(c) |
| ☒ | Rule 13d-1(d) |
* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures
provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but
shall be subject to all other provisions of the Act (however, see the Notes).
| CUSIP No. 1483C-105 | 13G | Page 2 of 5 Pages |
| | 1 | Names of Reporting Persons Derek J. Maetzold | |||
| | |||||
| | 2 | Check the Appropriate Box if a Member of a Group | |||
| | | (a) | ☐ | ||
| | | (b) | ☐ | ||
| | |||||
| | 3 | SEC Use Only | |||
| | |||||
| | 4 | Citizenship or Place of Organization United States of America | |||
| Number of Shares Beneficially Owned by Each Reporting Person With: | 5 | Sole Voting Power 1,953,215 Shares (1) | |||
| | |||||
| 6 | Shared Voting Power 0 Shares | ||||
| | |||||
| 7 | Sole Dispositive Power 1,953,215 Shares (1) | ||||
| | |||||
| 8 | Shared Dispositive Power 0 Shares | ||||
| | |||||
| | 9 | Aggregate Amount Beneficially Owned by Each Reporting Person 1,953,215 Shares | |||
| | |||||
| | 10 | Check if the Aggregate Amount in Row (9) Excludes Certain Shares ☐ | |||
| | |||||
| | 11 | Percent of Class Represented by Amount in Row (9) 11.3% (2) | |||
| | |||||
| | 12 | Type of Reporting Person IN | |||
(1) Includes (a) 217,165 shares of common stock issuable within 60 days of December 31, 2019 upon the exercise of stock options held by the Reporting Person, and (b) 164,068 shares held in
the name of the DJM Grantor Retained Annuity Trust No. 1, of which the Reporting Person is the Trustee.
(2) This percentage is calculated based on 17,074,049 shares of common stock outstanding as of November 7, 2019, as reported in the Issuer’s Quarterly Report on Form 10-Q filed on November
12, 2019.
| CUSIP No. 1483C-105 | 13G | Page 3 of 5 Pages |
| Item 1(a). | | Name of Issuer: Castle Biosciences, Inc. |
| Item 1(b). | | Address of Issuer’s Principal Executive Offices: 820 S. Friendswood Drive, Suite 201 Friendswood, TX 77546 |
| Item 2(a). | | Names of Persons Filing: Derek J. Maetzold |
| Item 2(b). | | Address of Principal Business Office, or, if none, Residence: 820 S. Friendswood Drive, Suite 201 Friendswood, TX 77546 |
| Item 2(c). | | Citizenship: United States of America |
| Item 2(d). | | Title of Class of Securities: Common Stock |
| Item 2(e). | | CUSIP No.: 14843C 105 |
| Item 3. | | Not Applicable. |
| Item 4. | Ownership | |
The following information with respect to the ownership of the Common Stock of the Issuer by the Reporting Person is provided as of December 31, 2019:
| (a) | Amount beneficially owned |
| | See Row 9 of cover page. |
| (b) | Percent of Class: |
| See Row 11 of cover page. |
| (c) | Number of shares as to which such person has: |
| (i) Sole power to vote or to direct the vote: See Row 5 of cover page. |
| (ii) Shared power to vote or to direct the vote: See Row 6 of cover page. |
| (iii) Sole power to dispose or to direct the disposition of: See Row 7 of cover page. |
| (iv) Shared power to dispose or to direct the disposition of: See Row 8 of cover page. |
| Item 5. | Ownership of Five Percent or Less of a Class. |
| If this statement is being filed to report the fact that as of the date hereof, the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the
following: ☐ | |
| | |
| Item 6. | Ownership of More than Five Percent on Behalf of Another Person |
| Not applicable | |
| CUSIP No. 1483C-105 | 13G | Page 4 of 5 Pages |
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person |
| Not applicable | |
| | |
| Item 8. | Identification and Classification of Members of the Group |
| Not applicable | |
| | |
| Item 9. | Notice of Dissolution of Group |
| Not applicable | |
| CUSIP No. 1483C-105 | 13G | Page 5 of 5 Pages |
| Item 10. | Certifications |
| By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired
and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose
or effect. | |
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: February 12, 2020
| | /s/ Derek J. Maetzold |
| | Derek J. Maetzold |